<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04902586</url>
  </required_header>
  <id_info>
    <org_study_id>ZhongnanH ECTG001</org_study_id>
    <nct_id>NCT04902586</nct_id>
  </id_info>
  <brief_title>Effect of Radiotherapy Concurrent of TTFields in Patients With Glioblastoma</brief_title>
  <acronym>ECTG001</acronym>
  <official_title>The Clinical Effect and Safety of Radiotherapy Concurrent of TTFields in the Treatment of Post-operation Patients With Glioblastoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhongnan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhongnan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TTFields has been approved by the FDA for the treatment of patients with glioblastoma&#xD;
      multiforme. However, the clinical effect and safety of radiotherapy concurrent of TTFields is&#xD;
      not definite. In this study, the investigators conduct a phase II clinical trial to evaluate&#xD;
      the efficacy and safety of this strategy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      the investigators plan to recruit 30 patients to evaluate the efficacy and safety of this&#xD;
      strategy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 19, 2021</start_date>
  <completion_date type="Anticipated">July 19, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 19, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>1 year</time_frame>
    <description>the length of time after primary treatment for glioblastoma ends that the patient survives without any signs or symptoms of glioblastoma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>The length of time from the date of diagnosis to death from cancer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Glioma</condition>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>E group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients received chemoradiotherapy (CRT) ( PTV-GTV: 60Gy at 2.0Gy per fraction, 5 fractions per week for 6 weeks; PTV-CTV: 54Gy at 1.8Gy per fraction, 5 fractions per week for 6 weeks) with a Temozolomide (TMZ) regimen（75mg/m2 per day during RT）and TTFields therapy during RT. The TTFields therapy started on the day the radiotherapy started.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>All patients received chemoradiotherapy (CRT) ( PTV-GTV: 60Gy at 2.0Gy per fraction, 5 fractions per week for 6 weeks; PTV-CTV: 54Gy at 1.8Gy per fraction, 5 fractions per week for 6 weeks) with a Temozolomide (TMZ) regimen（75mg/m2 per day during RT）</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TTFields</intervention_name>
    <description>The TTFields, consisting of low-intensity, 200 kHz frequency, alternating electric fields, was delivered (≥ 18 hours/d) via 4 transducer arrays on the shaved scalp and connected to a portable device.</description>
    <arm_group_label>E group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  performance status of 0-1 (Eastern Cooperative Oncology Group performance status)&#xD;
&#xD;
          -  histologically confirmed glioblastoma&#xD;
&#xD;
          -  no cerebrospinal fluid and distant metastatic disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  with a history of brain radiotherapy&#xD;
&#xD;
          -  severe hepatic and renal dysfunction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianyin Huang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wuhan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yahua Zhong, PHD</last_name>
    <phone>08602767813154</phone>
    <email>doctorzyh73@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongnan hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yahua Zhong, phd</last_name>
      <phone>08602767813154</phone>
      <email>doctorzyh73@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2021</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glioblastoma</keyword>
  <keyword>TTFields</keyword>
  <keyword>radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

